OKYO Pharma files 6-K; Exhibit 99.1 furnishes conference update

Rhea-AI Filing Summary

OKYO Pharma (OKYO) filed a Form 6-K announcing that Chief Executive Officer Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.

The related news announcement is furnished as Exhibit 99.1. The company states this exhibit is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2025

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 29, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing, that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: October 29, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated October 29, 2025

4

FAQ

What did OKYO (OKYO) announce in this Form 6-K?

The company announced that CEO Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna.

Who from OKYO will present and at what event?

Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at BIO-Europe.

Where is the 33rd Annual BIO-Europe conference being held?

The conference is in Vienna, Austria.

What is included as Exhibit 99.1?

A News Announcement dated October 29, 2025.

How is Exhibit 99.1 treated legally?

It is furnished, not deemed filed under Section 18 of the Exchange Act, and not incorporated by reference unless expressly stated.

When was the 6-K dated and signed?

It is dated October 29, 2025, signed by Keeren Shah, Chief Financial Officer.